NO20001400L - Kombinasjon av en monoaminooksidaseinhibitor og en h5-HT1B antagonist eller partiell agonist - Google Patents

Kombinasjon av en monoaminooksidaseinhibitor og en h5-HT1B antagonist eller partiell agonist

Info

Publication number
NO20001400L
NO20001400L NO20001400A NO20001400A NO20001400L NO 20001400 L NO20001400 L NO 20001400L NO 20001400 A NO20001400 A NO 20001400A NO 20001400 A NO20001400 A NO 20001400A NO 20001400 L NO20001400 L NO 20001400L
Authority
NO
Norway
Prior art keywords
combination
monoamine oxidase
partial agonist
oxidase inhibitor
alkyl
Prior art date
Application number
NO20001400A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001400D0 (no
Inventor
Stefan Berg
Svante Ross
Seth-Olov Thorberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20001400D0 publication Critical patent/NO20001400D0/no
Publication of NO20001400L publication Critical patent/NO20001400L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20001400A 1997-09-18 2000-03-17 Kombinasjon av en monoaminooksidaseinhibitor og en h5-HT1B antagonist eller partiell agonist NO20001400L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703376A SE9703376D0 (sv) 1997-09-18 1997-09-18 A new combination
PCT/SE1998/001602 WO1999013878A1 (en) 1997-09-18 1998-09-09 A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST

Publications (2)

Publication Number Publication Date
NO20001400D0 NO20001400D0 (no) 2000-03-17
NO20001400L true NO20001400L (no) 2000-05-05

Family

ID=20408296

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001400A NO20001400L (no) 1997-09-18 2000-03-17 Kombinasjon av en monoaminooksidaseinhibitor og en h5-HT1B antagonist eller partiell agonist

Country Status (27)

Country Link
US (1) US6159970A (enExample)
EP (1) EP1014986B1 (enExample)
JP (1) JP2001516719A (enExample)
KR (2) KR20010024087A (enExample)
CN (1) CN1278727A (enExample)
AR (1) AR013503A1 (enExample)
AT (1) ATE270889T1 (enExample)
AU (1) AU752719B2 (enExample)
BR (1) BR9812236A (enExample)
CA (1) CA2302204A1 (enExample)
DE (1) DE69825062T2 (enExample)
DK (1) DK1014986T3 (enExample)
EE (1) EE200000146A (enExample)
ES (1) ES2222603T3 (enExample)
HU (1) HUP0100621A2 (enExample)
ID (1) ID25789A (enExample)
IL (1) IL134775A0 (enExample)
IS (1) IS5401A (enExample)
MX (1) MXPA00002616A (enExample)
NO (1) NO20001400L (enExample)
PL (1) PL339368A1 (enExample)
PT (1) PT1014986E (enExample)
SE (1) SE9703376D0 (enExample)
SK (1) SK2832000A3 (enExample)
TR (1) TR200000725T2 (enExample)
WO (1) WO1999013878A1 (enExample)
ZA (1) ZA987804B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957948A (en) * 1988-05-05 1990-09-18 Interface, Inc. Biocidal protective coating for heat exchanger coils
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
ES2323451T7 (es) * 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US20090054453A1 (en) * 2006-03-17 2009-02-26 Lilian Alcaraz Novel Tetralins as 5-HT6 Modulators
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
EA200901140A1 (ru) 2007-03-01 2010-04-30 Пробиодруг Аг Новое применение ингибиторов глутаминилциклазы
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
CN102695546B (zh) 2009-09-11 2014-09-10 前体生物药物股份公司 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
SG183229A1 (en) 2010-03-10 2012-09-27 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
CN110179988A (zh) * 2019-07-10 2019-08-30 王大伟 五羟色胺再摄取抑制剂和单胺氧化酶抑制剂联合在制备治疗抑郁症或早泄药物中的应用
EP4633638A1 (en) * 2022-12-14 2025-10-22 Luminous Mind Inc. Treatment of psychological factors affecting other medical conditions (pfaomc)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DE69232003T2 (de) * 1991-09-18 2002-04-25 Glaxo Group Ltd., Greenford Benzanilidderivate als 5-HT1D-Antagonisten
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
US6159970A (en) 2000-12-12
DE69825062D1 (de) 2004-08-19
SK2832000A3 (en) 2000-09-12
CA2302204A1 (en) 1999-03-25
NO20001400D0 (no) 2000-03-17
SE9703376D0 (sv) 1997-09-18
ZA987804B (en) 1999-03-18
HUP0100621A2 (hu) 2001-08-28
ES2222603T3 (es) 2005-02-01
AU752719B2 (en) 2002-09-26
EP1014986A1 (en) 2000-07-05
JP2001516719A (ja) 2001-10-02
MXPA00002616A (es) 2002-04-24
DK1014986T3 (da) 2004-10-25
IS5401A (is) 2000-03-14
EE200000146A (et) 2001-02-15
CN1278727A (zh) 2001-01-03
ID25789A (id) 2000-11-02
ATE270889T1 (de) 2004-07-15
AR013503A1 (es) 2000-12-27
PT1014986E (pt) 2004-10-29
EP1014986B1 (en) 2004-07-14
KR20010024084A (ko) 2001-03-26
PL339368A1 (en) 2000-12-18
BR9812236A (pt) 2000-07-18
KR20010024087A (ko) 2001-03-26
IL134775A0 (en) 2001-04-30
TR200000725T2 (tr) 2000-08-21
DE69825062T2 (de) 2005-08-25
AU9193198A (en) 1999-04-05
WO1999013878A1 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
NO20001400L (no) Kombinasjon av en monoaminooksidaseinhibitor og en h5-HT1B antagonist eller partiell agonist
MY116280A (en) A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
WO2003062259A3 (en) Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
NO306237B1 (no) Anvendelse av xantinderivater som antidepressive midler
WO2001077107A8 (en) Oxazole derivatives and their uses as tyrosine kinase inhibitors
KR930702337A (ko) 메틸렌-옥스인돌 유도체 및 이의 제조방법
NO20002121L (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
SE0202463D0 (sv) Novel compounds
DK1569899T3 (da) Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
NO308248B1 (no) Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat
BR0314455A (pt) Derivados de aminoálcool, seus sais e agentes imunosupressores
DE69221721D1 (de) Ethanolaminderivate mit anti-pollakiurawirkung
DK0882726T3 (da) Carbazolcarboxamider som 5-HT1F-agonister
EP0725068A4 (en) INDOLDER DERIVATIVES
NO951980D0 (no) Anvendelse av dimetylbenzofuraner og dimetylbenzopyraner som 5-HT -antagonister
FI951631A0 (fi) Substituoituja kynureniinejä, menetelmä niiden valmistamiseksi ja niiden käyttö lääkkeinä
DK0861250T3 (da) Amindin- og isothiourinstofderivater som inhibitorer for nitrogenmonoxidsyntase
WO1995001170A3 (en) Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders
PL290676A1 (en) Method of obtaining novel derivatives of 2-aminoalkyl-5-diaryl-alkyl-1.3-dioxane
FI945582A0 (fi) Substituoidut (aryylialkyyliaminobentsyyli) aminopropioniamidijohdannaiset, niiden valmistus ja käyttö anti-epileptisinä, neuroprotektiivisina ja antidepressiivisina aineina
DK1169029T3 (da) Anvendelse af sibutramin eller et derivat deraf til behandling af sövnforstyrrelser
MY116281A (en) A combination of a selective 5-ht 1a antagonist and a selective h5-ht 1b antagonist or partial agonist.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application